<code id='109C6175F9'></code><style id='109C6175F9'></style>
    • <acronym id='109C6175F9'></acronym>
      <center id='109C6175F9'><center id='109C6175F9'><tfoot id='109C6175F9'></tfoot></center><abbr id='109C6175F9'><dir id='109C6175F9'><tfoot id='109C6175F9'></tfoot><noframes id='109C6175F9'>

    • <optgroup id='109C6175F9'><strike id='109C6175F9'><sup id='109C6175F9'></sup></strike><code id='109C6175F9'></code></optgroup>
        1. <b id='109C6175F9'><label id='109C6175F9'><select id='109C6175F9'><dt id='109C6175F9'><span id='109C6175F9'></span></dt></select></label></b><u id='109C6175F9'></u>
          <i id='109C6175F9'><strike id='109C6175F9'><tt id='109C6175F9'><pre id='109C6175F9'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:6464
          People in business and medical wardrobe in a table discussion — coverage from STAT
          Adobe

          R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private.

          Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

          advertisement

          In response to the offer, R1 asked New Mountain Capital to “engage in good faith discussions” with its largest investor — a partnership between Ascension, the large Catholic hospital system, and private equity firm TowerBrook Capital Partners. New Mountain Capital has since held several in-person meetings with Ascension and TowerBrook throughout February, but maintained its original offer for R1. No deal has been finalized yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          ADCs take center stage as promising cancer treatments
          ADCs take center stage as promising cancer treatments

          AtESMO2023,antibody-drugconjugateswerefeaturedprominently.AndrewJoseph/STATMADRID—Ifyouhadtopinpoint

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          UnitedHealth, Optum discontinue NaviHealth name

          MarkLennihan/APUnitedHealthGroupandOptumaregettingridofthenameoftheirtech-drivencaremanagementcompan